| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
61,820,000 |
| Market
Cap: |
174.95(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.62 - $4.13 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Poseida Therapeutics is a clinical-stage biopharmaceutical company. Co.'s chimeric antigen receptor T cell (CAR-T) product candidate includes P-BCMA-101, which is an autologous CAR-T being developed for the treatment of patients with metastatic castrate resistant prostate cancer. Co.'s dual CAR-T allogeneic program candidates include P-CD19CD20-ALLO1, which is an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for B cell leukemia and lymphoma indications and some autoimmune disease. Co.'s gene therapy programs include P-OTC-101, which is an in vivo liver-directed gene therapy candidate for the treatment of ornithine transcarbamylase deficiency.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
2,292,857 |
| Total Buy Value |
$0 |
$0 |
$0 |
$8,025,000 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
160,696 |
| Total Sell Value |
$0 |
$0 |
$0 |
$592,808 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ostertag Eric |
Chief Executive Officer |
• • • |
2021-06-02 |
4 |
AS |
$8.34 |
$339,621 |
I/I |
(40,722) |
3,469,958 |
|
-20% |
|
| Ostertag Eric |
Chief Executive Officer |
• • • |
2021-06-01 |
4 |
AS |
$8.61 |
$354,680 |
I/I |
(41,194) |
3,489,434 |
|
-22% |
|
| Ostertag Eric |
Chief Executive Officer |
• • • |
2021-05-04 |
4 |
AS |
$8.44 |
$303,722 |
I/I |
(35,986) |
3,509,135 |
|
-1% |
|
| Ostertag Eric |
Chief Executive Officer |
• • • |
2021-05-03 |
4 |
AS |
$9.01 |
$165,117 |
I/I |
(18,326) |
3,526,346 |
|
-8% |
|
| Spear Matthew A. |
Chief Medical Officer |
• – – |
2021-04-23 |
4 |
OE |
$1.32 |
$6,610 |
D/D |
5,000 |
16,485 |
|
- |
|
| Spear Matthew A. |
Chief Medical Officer |
• – – |
2021-04-21 |
4 |
AS |
$8.44 |
$33,752 |
D/D |
(4,000) |
11,485 |
|
20% |
|
| Spear Matthew A. |
Chief Medical Officer |
• – – |
2021-04-21 |
4 |
OE |
$1.32 |
$5,288 |
D/D |
4,000 |
15,485 |
|
- |
|
| Ostertag Eric |
Chief Executive Officer |
• • • |
2021-03-02 |
4 |
AS |
$11.54 |
$658,415 |
I/I |
(57,060) |
3,590,111 |
|
-19% |
|
| Ostertag Eric |
Chief Executive Officer |
• • • |
2021-03-01 |
4 |
AS |
$11.66 |
$676,046 |
I/I |
(57,940) |
3,617,401 |
|
-20% |
|
| Ostertag Eric |
Chief Executive Officer |
• • • |
2021-02-23 |
4 |
OE |
$1.17 |
$130,666 |
D/D |
111,395 |
542,985 |
|
- |
|
| Ostertag Eric |
Chief Executive Officer |
• • • |
2021-02-16 |
4 |
AS |
$10.00 |
$1,332,036 |
I/I |
(133,149) |
200,696 |
|
-0% |
|
| Ostertag Eric |
Chief Executive Officer |
• • • |
2021-02-10 |
4 |
AS |
$10.00 |
$123,890 |
I/I |
(12,389) |
333,845 |
|
-7% |
|
| Ostertag Eric |
Chief Executive Officer |
• • • |
2021-02-10 |
4 |
OE |
$1.29 |
$87,119 |
D/D |
67,534 |
431,590 |
|
- |
|
| Ostertag Eric |
Chief Executive Officer |
• • • |
2021-01-21 |
4 |
AS |
$10.00 |
$44,620 |
I/I |
(4,462) |
346,234 |
|
-17% |
|
| Spear Matthew A. |
Chief Medical Officer |
• – – |
2021-01-15 |
4 |
OE |
$1.32 |
$10,000 |
D/D |
7,564 |
11,485 |
|
- |
|
| Mylet Johanna |
Senior Vice President, Finance |
• – – |
2021-01-15 |
4 |
OE |
$0.30 |
$1,418 |
D/D |
4,728 |
26,813 |
|
- |
|
| Spear Matthew A. |
Chief Medical Officer |
• – – |
2021-01-08 |
4 |
OE |
$1.32 |
$5,184 |
D/D |
3,921 |
3,921 |
|
- |
|
| Novartis Ag |
10% Owner |
– – • |
2020-07-14 |
4 |
A |
$0.00 |
$0 |
D/D |
5,908,089 |
5,908,089 |
|
- |
|
| Lloyd Marcea Bland |
Director |
– • – |
2020-07-14 |
4 |
B |
$16.00 |
$160,000 |
D/D |
10,000 |
10,000 |
2.39 |
-14% |
|
| Murphy Sean |
Director |
– • • |
2020-07-14 |
4 |
B |
$16.00 |
$160,000 |
D/D |
10,000 |
10,000 |
3.92 |
-14% |
|
| Murphy Sean |
Director |
– • • |
2020-07-14 |
4 |
A |
$0.00 |
$0 |
I/I |
9,188,125 |
9,188,125 |
|
- |
|
| Malin Corp Plc |
10% Owner |
– – • |
2020-07-14 |
4 |
A |
$0.00 |
$0 |
D/D |
9,188,125 |
9,188,125 |
|
- |
|
| Ostertag Eric |
Chief Executive Officer |
• • • |
2020-07-14 |
4 |
A |
$0.00 |
$0 |
I/I |
606,541 |
350,696 |
|
- |
|
| Hirsch David |
Director |
– • – |
2020-07-14 |
4 |
B |
$16.00 |
$4,000,000 |
I/I |
250,000 |
2,714,245 |
2.1 |
-14% |
|
| Hirsch David |
Director |
– • – |
2020-07-14 |
4 |
A |
$0.00 |
$0 |
I/I |
2,464,245 |
2,464,245 |
|
- |
|
103 Records found
|
|
Page 4 of 5 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.04 (1.39%) 
